Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

308.16 -1.73 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,946,059
Open 313.13
Bid (Size) 308.16 (2)
Ask (Size) 309.70 (1)
Prev. Close 309.89
Today's Range 307.29 - 313.44
52wk Range 218.44 - 329.72
Shares Outstanding N/A
Dividend Yield 2.76%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
+3.62%
+3.62%
1 Month
-0.40%
-0.40%
3 Month
+11.58%
+11.58%
6 Month
+8.45%
+8.45%
1 Year
+34.18%
+34.18%

More News

Read More
Where Will Amgen Be in 5 Years?
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
Via Benzinga
Expert Ratings For Amgen
Via Benzinga
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Via InvestorPlace
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Via Benzinga
Where Will Amgen Be in 3 Years?
Via The Motley Fool
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
3 Stocks to Buy as Ozempic Surges in Popularity
Via InvestorPlace
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
Via Investor's Business Daily
Is Geron Stock a Buy Following Its First New Drug Approval?
Via The Motley Fool
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Via Benzinga
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Via The Motley Fool
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Via Benzinga
Exposures Product Safety
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Via InvestorPlace
Topics ETFs
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Via The Motley Fool
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Via Benzinga
Exposures Product Safety
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.